Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20060094608 A1
Publication typeApplication
Application numberUS 11/299,884
Publication date4 May 2006
Filing date12 Dec 2005
Priority date1 May 2002
Also published asCA2484275A1, CA2484275C, DE60328475D1, EP1499290A1, EP1499290B1, EP2108359A1, EP2108359B1, US7005408, US7285517, US7758887, US20030207772, US20030211161, US20030232090, WO2003092651A1
Publication number11299884, 299884, US 2006/0094608 A1, US 2006/094608 A1, US 20060094608 A1, US 20060094608A1, US 2006094608 A1, US 2006094608A1, US-A1-20060094608, US-A1-2006094608, US2006/0094608A1, US2006/094608A1, US20060094608 A1, US20060094608A1, US2006094608 A1, US2006094608A1
InventorsNawaz Ahmad, Ying Sun, Shun Lin
Original AssigneeNawaz Ahmad, Ying Sun, Lin Shun Y
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Warming and nonirritating lubricant compositions and method of comparing irritation
US 20060094608 A1
Abstract
This invention relates to substantially anhydrous warming, non-toxic and nonirritating lubricating compositions containing polyhydric alcohols and an insulating agent. The invention also relates to methods of using such compositions for lubrication, administration of active ingredients and for preventing or treating dysmenorrhea.
Images(5)
Previous page
Next page
Claims(9)
1. A substantially anhydrous lubricant composition comprising at least one polyhydric alcohol and an insulating agent.
2-14. (canceled)
15. A method of treating or preventing dysmenorrhea comprising applying a composition comprising from about 80% to about 98% by weight polyhydric alcohol and less than about 20% by weight water intravaginally.
16-18. (canceled)
19. A method of providing personal lubrication to a human's oral or vaginal mucosa during intercourse comprising applying to the oral or vaginal mucosa a composition comprising a substantially anhydrous lubricant composition which conveys a feeling of warmth upon application comprising at least one polyhydric alcohol.
20. A method of providing personal lubrication to a human's vaginal mucosa during intercourse comprising applying to the vaginal mucosa a composition comprising a substantially anhydrous lubricant composition which conveys a feeling of warmth upon application comprising at least one polyhydric alcohol.
21. A method according to claim 19 wherein said polyhydric alcohol is selected from the group consisting of: glycerin, alkylene glycol, polyethylene glycol and a mixture thereof.
22. A method according to claim 21 wherein said composition comprises from about 80% to about 98% by weight polyhydric alcohol
23. A method according to claim 28 wherein said composition comprises about 50% by weight propylene glycol and about 45% by weight glycerin.
Description
    FIELD OF THE INVENTION
  • [0001]
    This invention relates to personal lubricant compositions that are warming and nonirritating when applied to the skin or mucous membranes, especially the vaginal or oral mucosa. The compositions of this invention are substantially anhydrous and contain one or more polyhydric alcohol. This invention also relates to the method that can be used to test and compare the irritation of the compositions of this invention and other personal lubricants known to the art.
  • BACKGROUND OF THE INVENTION
  • [0002]
    In the field of personal lubricants and medicaments applied to mucosal membranes, from time to time attempts have been made to overcome the problem of the perception of cold. When an individual applies personal lubricant or medicament such compositions to internal mucosal membranes, often an individual experiences an uncomfortable, cold feeling due to the difference in temperature between the body and the ambient temperature.
  • [0003]
    An appreciable number of personal lubricant compositions are known to the art. These compositions range from jellies to liquids to vaginal suppositories and vary from being aqueous to oils to silicone based. The majority of the compositions actually used today are aqueous jellies or aqueous liquids. Almost all personal lubricants known and available for use today are cold to touch, a feeling that can be uncomfortable.
  • [0004]
    A number of compositions are known to the trade or described in the literature that claim to impart a warming sensation upon application to the skin or mucosa. Some of these compositions use plant extracts which are irritating to the skin and mucous membranes and give a feeling or perception of warmth by virtue of their irritant action. Others claim to enhance blood flow in order to cause tissue warming. Still others are alleged to work on the principle of freezing point depression and are well suited for heating in a microwave or cooling in a refrigerator. There is one cosmetic composition rendered self-heating by inclusion of compound containing a boron-to-boron linkage, which reacts exothermally with water.
  • [0005]
    One example of a composition known to the trade, Prosensual™, distributed by Lexie Trading, Inc., Fairlaw, N.J., contains plant extracts such as Cinnamon cassia (Cinnamon), Zingiber officinalis (Ginger), Mint, Sandalwood, Orange and Clove, which are all known to be skin irritants. Such a composition has the disadvantage of causing irritation to the mucosa, which can be problematic in relation to the vaginal or oral mucosa as irritation may promote the growth of unwanted bacteria and cause infection.
  • [0006]
    Another current composition, WET™ Heating Massage Oil, distributed by International, Valencia, Calif., uses Retinyl Palmitate (Vitamin A Palmitate), Prunus amygdalis (Prunes), Amara (Almond), Persica gratissima (Avacado Oil), Macdamia ternifulia Seed Oil, Kakeri Nut Oil, Helianthus annus (hybrid Sunflower), Cannabis sativa (Hemp) Seed Oil and Aloe vera. Most of these ingredients are known irritants that are not suitable for use on mucous membranes.
  • [0007]
    U.S. Pat. No. 5,895,658, entitled “Delivery of L-Arginine to Cause Tissue Warming, Sustained Release of Nitric Oxide to treat effects of Diabetes, Stimulate Hair Growth and Heal Wounds,” describes a preparation for producing enhanced blood flow in tissues thus causing beneficial effects, such as warming cold tissues of hands and feet.
  • [0008]
    U.S. Pat. No. 5,513,629 entitled “Microwavable Heat Releasing and Absorbing Compositions and Container, Pliable Gel Comprising Humectant, Freezing Point Depressant, Gel Sealer, Polyacrylamide Absorbent, Corn Starch Binder, Mineral Oil and Plasticizers, Durability, Efficacy” describes compositions that have a high vapor points and are, therefore, suited for heating in a microwave oven or cooling in a freezer and placement in a suitable container or vinyl package, such as a hot-and-cold pack, but not for human consumption or use.
  • [0009]
    However, none of the foregoing compositions are actually “warm”, or at a relatively higher temperature than the ambient temperature of the product or the surrounding environment.
  • [0010]
    U.S. Pat. No. 4,110,426, entitled “Method of Treating Skin and Hair with a Self Heated Cosmetic, Organic Boron-Oxygen-Boron Compounds” describes non-aqueous compositions such as shaving creams, that are rendered self-heating by including therein a compound containing at least one boron-oxygen-boron linkage, such as triethoxyboroxine. The boron-containing compound reacts exothermally with water or other protic material to increase temperature. Such compositions are not suitable for vaginal or oral use due to the potential toxicity of boron-containing compounds to the human reproductive system (Fail P A, et al., general, reproductive, developmental, and endocrine toxicity of boronated compounds, Reprod toxicol 12: 1, 1-18, January-February, 1998).
  • [0011]
    Physical energy forms have been utilized to enhance material transport across a membrane for therapeutic purposes. Such energy forms include electricity, ultrasound and thermal energy (e.g., heat-assisted drug delivery), (reviewed by Sun, in “Skin Absorption Enhancement by Physical Means: Heat, Ultrasound, and Electricity”, Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc., 1997, pages 327-355). Local heating of a drug delivery system or formulation, as well as the skin or mucosal tissues, not only increases thermodynamic energy of drug molecules and membrane permeability to facilitate drug movement across a barrier membrane, it improves blood circulation in the tissue to expedite drug removal from the local tissue into the systemic circulation. Both processes leads to an enhanced absorption of the drug. Experimental evidence demonstrates that low-level heating (i.e., a tissue temperature of less than about 42° C.) significantly enhances percutaneous drug absorption.
  • [0012]
    U.S. Pat. No. 5,658,583 describes a heat-generating apparatus for improved dermal permeation of pharmaceuticals. The apparatus includes a thin drug formulation reservoir and a heat-generating chamber of oxidation reaction separated by a non-permeable wall. The drug formulation reservoir houses a predetermined amount of a formulation containing pharmaceutical agents. The heat-generating/temperature-regulating chamber includes a heat-generating medium consisting of carbon, iron, water and/or salt which is activated upon contact with oxygen in the air. However, a complicated heating device such as this is not suitable for use in the vaginal or oral cavity for obvious safety concerns.
  • [0013]
    Locally applied heat (such as an abdominal heating patch) has also been used to treat dysmenorrhea, or menstrual cramps, with demonstrated efficacy (Akin M D et al., Continuous low-level topical heat in the treatment of dysmenorrhea., Obstet Gynecol 97: 3, 343-9, March, 2001).
  • [0014]
    U.S. Pat. No. 6,019,782 describes disposable thermal body pads with heat generation via an oxidation reaction intended for relieving menstrual pain when applied onto the abdominal skin. There is currently a commercial product in the U.S. market for dysmenorrhea treatment based on abdominal heating, ThermaCare® Air-Activated Heatwraps, Menstrual Cramp Relief patches manufactured by Procter & Gamble (Cincinnati, Ohio). However, there are no products or description of internal localized heating to treat dysmenorrhea.
  • SUMMARY OF THE INVENTION
  • [0015]
    The compositions and methods of this invention relate to warming lubricant compositions that are non-toxic and non-irritating and that can be used as personal lubricants designed to come into contact with the skin or mucosa. When mixed with water, the compositions of this invention increase in temperature or generate warmth. This has a soothing effect on the tissues to which these compositions are applied.
  • [0016]
    The compositions of this invention may be applied to the skin or mucous membranes, preferably the vaginal or oral mucosa. The compositions of this invention are preferably substantially anhydrous and preferably contain at least one polyhydric alcohol.
  • [0017]
    We theorize that, when the polyhydric alcohols contained in the compositions of this invention come into contact with water or body moisture in humans, they react with the ambient water molecules to cause an increase in temperature or generate warmth, thus having a soothing effect on the tissues to which these compositions are applied.
  • [0018]
    Surprisingly, and contrary to the general belief that polyhydric alcohols in compositions are irritating to the mucosa, compositions of this invention containing such polyhydric alcohols have been found to be non-irritating. In fact, these compositions are very mild to the skin and mucous membranes. The compositions of this invention are soothing when applied to oral mucous membranes and may function to relieve minor irritation of the mouth and throat.
  • [0019]
    The combination of polyhydric alcohols in the compositions of this invention may also be used as a vehicle to solubilize otherwise insoluble drugs, including, but not limited to, antifungals, antibacterials, antivirals, analgesics, anti-inflammatory steroids, contraceptives, local anaesthetics, hormones and the like.
  • [0020]
    The compositions of this invention also preferably contain an insulating agent which functions to preserve the temperature increase by maintaining the heat within the composition after it has been applied to the skin or mucosa. More preferably, honey may be utilized as an insulating agent.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0021]
    FIG. 1 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 1.
  • [0022]
    FIG. 2 is a graph depicting the % viable Epiderm cells vs Exposure Time using the composition of Example 2.
  • [0023]
    FIG. 3 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art non-irritating Product (K-Y Liquid@)
  • [0024]
    FIG. 4 is a graph depicting the % viable Epiderm cells vs Exposure Time using a State-of-the-Art warming Product (Prosensual®)
  • [0025]
    FIG. 5 is a graph comparing the Lubricity vs Time (Seconds) of the composition of Example 1 and three leading Personal Lubricants on the market.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0026]
    The compositions of this invention are substantially anhydrous, preferably containing less than about 20% water, more preferably containing less than about 5% water and, most preferably, containing less than about 3% water. Preferably, the compositions of this invention contain at least one polyhydric alochol, and more preferably, two polyhydric alcohols. Preferably the polyhydric alcohol portion of the compositions of this invention one or more polyhydric alcohols such as alkylene glycols and others selected from the following group: glycerin, propylene glycol, butylene glycol, hexalene glycol or polyethylene glycol of various molecular weight and the like and/or combination thereof. More preferably, the compositions of this invention contain a polyethylene glycol; most preferably, the polyethylene glycol may be selected from the following group: polyethylene glycol 400 or polyethylene glycol 300. The compositions of this invention should contain polyhydric alcohols in an amount from about 80% to about 98% by weight of the composition.
  • [0027]
    The compositions of this invention preferably also contain an insulating agent. More preferably, the insulating agent should be honey or esters of isopropyl alcohol and saturated high molecular weight fatty acids such as myristic or palmitic acid, e.g., isopropyl myristate and isopropyl palmitate. The insulating agent should be present in the compositions of this invention in an amount of from about 1% to about 5% by weight of the composition.
  • [0028]
    The compositions of this invention are unexpectedly self-preserving and may not require a preservative. However, a preservative may be added to impart an additional guarantee against microbial growth. A preservative may be selected from preservatives known to those of skill in the art, including, but not limited to, one or more of the following: methylparaben, benzoic acid, sorbic acid, gallic acid, propylparaben or the like. The preservative may be present in the compositions of this invention in an amount from about 0.01% to about 0.75% by weight of the composition.
  • [0029]
    The compositions of this invention may also preferably contain an ester. More preferably, the ester is a fatty acid ester. Most preferably, the ester may include, but is not limited to: isopropyl stearate, isopropyl myristate, isopropyl palmitate, isopropyl laurate and the like. Most preferably, the ester is isopropyl myristate.
  • [0030]
    The compositions of this invention may contain one or more water-soluble cellulose-derived polymers, gums, chitosans or the like. Such polymers contribute to the viscosity and bioadhesiveness of the compositions of this invention. Preferably, such cellulose-derived polymers are hydroxyalkylcellulose polymers. More preferably, the hydroxyalkylcellulose polymer is hydroxypropylcellulose or Klucel®, available commercially from Hercules Incorporated, Wilmington, Del.
  • [0031]
    The polyhydric alcohols used in the compositions of this invention are theorized to be useful as warming and heat-generating agents. Honey functions as an insulating agent, protecting the compositions from becoming too cold. The ester, preferably a fatty acid ester, functions as an emollient and lubricant. The cellulose polymer is useful as a viscosity building agent. The compositions of this invention are unique in that they lubricate, warm and soothe the tissues of the user, especially the oral and vaginal mucous membranes, without conveying a feeling of cold. Moreover, they are smooth and lubricating.
  • [0032]
    The compositions of this invention may be a liquid, a semi-solid, or a solid depending upon the particular intended use thereof. The compositions of this invention may also be formulated into soft or hard gelatin capsules, suppositories and impregnated into fabrics or polymers.
  • [0033]
    The compositions of this invention may be used as personal lubricants which convey a feeling of warmth. The feeling of warmth generated by the compositions of this invention is soothing to the skin or mucous membranes where they are applied. The compositions of the invention also possess a sweet and pleasant taste, which is of particular benefit when these compositions are used orally.
  • [0034]
    The compositions of this invention may also be used as personal moisturizers, which convey a feeling of warmth when applied to vaginal or oral mucosa.
  • [0035]
    The compositions of this invention may also be used as a vehicle to deliver medication or other treatment agents to the biomembranes including, but not limited to, hormones, antimicrobial or antifungal agents and the like. The antifungal agents is preferably an azole or imidazole, including but not limited to, miconazole, econazole, terconazole, saperconazole, itraconazole, butaconazole, clotrimazole, tioconazole, fluconazole and ketoconazole, vericonazole, fenticonazole, sertaconazole, posaconazole, bifonazole, oxiconazole, sulconazole, elubiol, vorconazole, isoconazole, flutrimazole and their pharmaceutically acceptable salts and the like. Other antifungal agents may include an allylamine or one from other chemical families, including but not limited to, ternafine, naftifine, amorolfine, butenafine, ciclopirox, griseofulvin, undecyclenic acid, haloprogin, tolnaftate, nystatin, iodine, rilopirox, BAY 108888, purpuromycin and their pharmaceutically acceptable salts.
  • [0036]
    Another embodiment of the invention are compositions for vulvovaginal use containing one or more antibiotics. The antibiotic may be chosen from the group including, but not limited to, metronidazole, clindamycin, timidazole, ornidazole, secnidazole, refaximin, trospectomycin, purpuromycin and their pharmaceutically acceptable salts and the like.
  • [0037]
    Another embodiment of the compositions of this invention include compositions for vulvovaginal use containing one or more antiviral agents. Antiviral agents may preferably include, but are not limited to, immunomodulators, more preferably imiquimod, its derivatives, podofilox, podophyllin, interferon alpha, reticolos, cidofovir, nonoxynol-9 and their pharmaceutically acceptable salts and the like.
  • [0038]
    Still other embodiments of the compositions of this invention are compositions that include one or more spermicides. The spermicides may preferably include, but are not limited to, nonoxynol-9, octoxynol-9, dodecaethyleneglycol monolaurate, Laureth 10S, and Methoxypolyoxyethyleneglycol 550 Laurate and the like.
  • [0039]
    Still other embodiments of the compositions of this invention are compositions containing antimicrobial agents. The antimicrobial agents may preferably include, but are not limited to, chlorohexidine gluconate, sodium polystyrene sulfonate, sodium cellulose sulfate, silver particles of micro- and sub-micrometer sizes, silver salts and other antibacterial agents known to the art.
  • [0040]
    Yet other embodiments of the compositions of this invention are compositions that may include local anesthetics. The local anesthetics may preferably include, but are not limited to, benzocaine, lidocaine, dibucaine, benzyl alcohol, camphor, resorcinol, menthol and diphenylhydramine hydrochloride and the like.
  • [0041]
    Compositions of the invention may also include plant extracts such as aloe, witch hazel, chamomile, hydrogenated soy oil and colloidal oatmeal, vitamins such as vitamin A, D or E and corticosteroids such as hydrocortisone acetate.
  • [0042]
    Another embodiment of the compositions and methods of this invention include compositions for vulvovaginal use containing one or more hormones for treating a decrease in estrogen secretion in the woman in need of estrogen replacement such as women with vaginal atrophy. The hormones may preferably include, but are not limited to, estrogen selected from the group consisting of estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, conjugated estrogen, estriol, estrone, estrone sulfate, ethinyl estradiol, estrofurate, quinestrol and mestranol.
  • [0043]
    Another embodiment of the compositions and methods of this invention include compositions for vulvovaginal use containing one or more analgesics and/or nonsteroidal anti-inflammatory agents for treating dysmenorrhea or mentrual cramping. The analgesics and nonsteroidal anti-inflammatory agents may preferably include, but are not limited to, aspirin, ibuprofen, indomethacin, phenylbutazone, bromfenac, fenamate, sulindac, nabumetone, ketorolac, and naproxen and the like.
  • [0044]
    Yet another embodiment of the compositions and methods of this invention include compositions for oral and vulvovaginal use relates to a method of enhancing the absorption of active agents from the applied compositions into the mucosal membrane by increasing the composition and mucosal tissue temperature via interaction of the polyhydric alcohols in the compositions and moisture on the mucosa and subsequently released heat.
  • [0045]
    Yet another embodiment of the compositions of this invention include compositions for vulvovaginal use relates to compositions and methods for preventing and/or treating dysmenorrhea by intravaginal warming or heating. Preferably, the composition heats the intravaginal area to a temperature preferably between about 37° C. and about 42° C., more preferably between about 38° C. and about 41° C. The compositions of invention for use in such a method may optionally contain active agents such as analgesics and nonsteroidal anti-inflammatory agents for dysmenorrhea treatment. The composition of the invention may be administered directly into the vagina by an applicator, or be impregnated into vaginal devices such as tampon for intravaginal applications.
  • [0046]
    The compositions of this invention may be manufactured as a coating of a tampon, or dispersing throughout the absorbent tampon material, or enclosed inside as a core of a tampon. The compositions of this invention for the warming tampon for preventing and/or treating dysmenorrhea preferably include a mixture of polyethylene glycols of various molecular weights produced by The Dow Chemical Company (Midland, Mich.) under the trade names of CARBOWAX SENTRY PEG 300 NF, CARBOWAX SENTRY PEG 400 NF, CARBOWAX SENTRY PEG 600 NF, CARBOWAX SENTRY PEG 900 NF, CARBOWAX SENTRY PEG 1000 NF, CARBOWAX SENTRY PEG 1450 NF, CARBOWAX SENTRY PEG 3500 NF, CARBOWAX SENTRY PEG 4000 NF, CARBOWAX SENTRY PEG 4600 NF, and CARBOWAX SENTRY PEG 8000 NF. The compositions of this invention for dysmenorrhea prophylaxis and treatment may contain one or more water-soluble cellulose-derived polymers and gums that form gels around the polyhydric alcohols such as glycerin, propylene glycol and polyethylene glycols thus reducing the dissolution of the polyhydric alcohols, prolonging the solvation heat release, and regulating the elevated temperature in the preferred temperature range.
  • [0047]
    This invention also relates to a method of determining and comparing relative amounts of irritation caused by particular sources using the EpiDerm™ Skin Model Assay as described in Example 1, such as compositions applied to skin or mucosal cells. The following Example 1 exemplifies the use of the method of this invention.
  • EXAMPLE 1 EpiDerm™ Skin Model Assay to Test Irritation of Lubricants
  • [0048]
    The method designated as EpiDerm™ Skin Model assay uses the epithelial cells derived from human skin as target cells and is commercially available from the MatTek Corporation. This assay is described in Berridge, M. V., et al. (1996) The Biochemical and Cellular Basis of Cell Proliferation Assays That Use Tetrazolium Salts. Biochemica 4: 14-19. The test materials are applied directly to the epithelial cell culture surface. This test has not previously been used for determining toxicity of test materials. The toxicity of the test material is evaluated on the basis of relative tissue viability vs time. The actual Tissue Viability is determined by NAD(P)H-dependent microsomal enzyme reduction of MTT in control and test article treated cultures. The negative control used in this assay was deionized water and the positive control was Triton X-100. The exposed cell cultures were incubated for 4, 8, 16 and 24 hours and assayed for reduction of MTT. The data is presented below in FIGS. 1 through 4 in the form of Relative Survival (relative MTT reduction) versus Exposure Time. Products with higher relative survival rates are less toxic or less irritating while the ones with lower survival rates are more toxic or irritating.
  • [0049]
    FIGS. 1 through 4 summarize the results of Epiderm Skin. Model Bioassay. The data is plotted as % Viable Cells vs the Exposure Time ranging from 4 to 24 hours. FIGS. 1 and 2 represent the results for two compositions of this invention, Composition 1 and Composition 2 respectively. FIG. 3 represents the results of K-Y® Liquid that is an established personal lubricant on the market. K-Y® Liquid is established as safe and nonirritating in animal and human testing and long-term human use history. Results for K-Y® Liquid showed 100.3% viable cells after 24 hour of exposure (FIG. 3).
  • [0050]
    Example 1 of the invention (FIG. 1) and Example 2 of the invention (FIG. 2) showed 91.1% and 96.9% viable cells respectively. FIG. 4 shows the results of a warming composition known to the trade. This product uses plant materials like cinnamon, clove, ginger cloves and orange and others for a warming sensation. The results show only 37.6% viable cells after 24 hours of exposure to this product. This indicates that such compositions will be irritating to the skin and mucous membranes. Compositions 1 and 2 of this invention, with 91.1% and 96.9% viable cells respectively, will be practically nonirritating. Positive control (Triton X-100) has only 22.4% viable cells at the 8-hour interval.
  • EXAMPLE 2 Generation Of Warmth
  • [0051]
    The compositions of this invention are anhydrous and contain one or more polyhydric alcohol. When combined with water, the polyhydric alcohols used in the compositions of this invention generate an increase in temperature that has a soothing effect on the tissues these compositions are applied. In actual use the compositions of the invention interact with the moisture of the vaginal or oral mucosa, thereby increasing the temperature or generating feeling of warmth.
  • [0052]
    The “Generation of warmth” data summarized in Table 1 below, was generated by mixing 20 ml of each of the ingredients in Composition 1 and Composition 1 of this invention with 20 ml of water. The temperature of the product and that of water were recorded before water was added to the product. After the addition of water the mixture was mixed for two minutes and the actual temperature was recorded. Glycerin, Propylene Glycol and Honey are the ingredients in Composition 1. It is clear from Table 1. that when mixed with water the temperature of the mixture rises by 9.0° F. for Glycerin, 13.5° F. for Propylene Glycol, 17.0° F. for Polyethylene Glycol 400 and 12.5° F. for composition Example 1 of this invention. The calculated rise in temperature for Composition 1, based on the rise in temperature and the % w/w quantity of each individual ingredient in the composition was 10.875° F. The actual recorded temperature rise for Composition 1. was 12.5° F. which is 1.625° F. higher than expected which indicates that there is an unexpected increase in temperature resulting from the combination of ingredients.
    GENERATION OF WARMTH (RISE IN TEMPERATURE ° F.) DATA BY MIXING EQUAL
    QUANTITY OF EACH PRODUCT WITH WATER
    Rise in
    Average Temperature
    Temperature Expected Actual (° F.)
    of the Product Temperature Temperature Temperature (Expected
    Product Name (° F.) of Water (° F.) (° F.) (° F.) Minus Actual)
    Glycerin 69.0 71.0 70.0 79.0 9.0
    Assay
    Propylene 72.4 71.0 71.7 85.2 13.5
    Glycol
    Assay
    Honey 74.0 71.0 72.5 74.0 1.5
    K-Y Warm ® 74.0 71.0 72.5 85.0 12.5
    Isopropyl 75.0 74.1 74.5 75.2 0.7
    Myristate
    Polysorbate 60 70.9 74.1 72.5 83.1 10.6
    Polyethylene 72.0 71.0 71.5 88.5 17.0
    Glycol 400
  • [0053]
    Calculated Rise in Temperature: In order to determine the expected rise in temperature from each composition, the percentage of each component in such composition was multiplied by the temperature increase generated by such component alone to obtain its expected contribution to the temperature increase. These values were added together to calculate the total expected temperature rise. These values were then compared with the actual temperature rise generated by each composition. For example, the calculated rise in temperature generated by the “K-Y Warm®” composition in the table above was found as follows and compared with the actual temperature rise to determine the unexpectedly higher generation of warmth of the composition:
    Propylene Glycol (50% of 13.5) = 6.75
    Glycerin (45% of 9.0) = 4.05
    Honey (5% of 1.5) = 0.075
    Total 10.875

    Difference: 12.5-10.875=1.625
  • EXAMPLE 3 Effect of Water Content on Generation of Warmth
  • [0054]
    On contact with moisture or water the heat of solution is responsible for the warming action of the compositions of this invention. There is a concern that accidental contamination with water or prolonged exposure to excessive moisture, the warming capacity of the product may be adversely effected. According to this example, water was added to compositions of this invention varying from about 1% to about 10% as outlined in Table 2 below. The contents were thoroughly mixed and the samples were allowed to stay at room temperature for 24 hour following which the generation of warmth was determined as outlined in the following paragraph. The results show that rise in temperature is proportionately decreased depending on the quantity of water added but there is still an 8.5° F. increase in temperature at about 10% water addition.
  • [0055]
    The results of this example are set forth in Table 2 below.
    TABLE 2
    Effect Of Water Content On Generation Of Warmth For
    K-Y Warm ®.
    Rise in
    Temperature
    Temperature Average (° F.)
    of the Temperature Expected Actual (Expected
    Sample of Water Temperature Temperature Minus
    Product Name (° F.) (° F.) (° F.) (° F.) Actual)
    No Water 73.80 70.00 71.90 83.50 11.60
    1% Water 73.90 70.00 71.95 82.20 10.25
    2% Water 72.30 70.00 71.95 81.70 9.85
    3% Water 72.30 70.00 71.15 80.40 9.25
    4% water 72.20 70.00 71.10 80.70 9.60
    5% Water 71.60 70.00 70.80 80.40 9.60
    6% Water 71.60 70.00 70.80 80.40 9.60
    7% Water 71.50 70.00 70.75 80.20 9.45
    8% Water 71.60 70.00 70.80 80.20 9.40
    9% Water 70.90 70.00 70.45 79.50 9.05
    10% Water  70.50 70.00 70.25 79.00 8.50
  • EXAMPLE 4 Perception Of Warmth In Human Use
  • [0056]
    A human use study was conducted with 246 subjects. The data generated by this study are summarized below in Table 2. The subjects were asked to use compositions of this invention. They were asked three questions regarding the perception of warmth while using the product, as follows:
    • 1. Does it warm on contact?
    • 2. Does it feel warm?
    • 3. Does it not feel cold?
  • [0060]
    The subjects were asked to register their response as Excellent, Very Good, Good, Fair and Poor. The positive responses are summarized in Table 2.
    TABLE 3
    PERCEPTION OF WARMTH IN HUMAN USE STUDY WITH 246
    HUMAN SUBJECTS USING COMPOSITION EXAMPLE 1 OF THE
    INVENTION
    QUESTION ASKED POSITIVE RESPONSE (%)
    Warms on Contact
    Excellent 25.12
    Very Good 31.88
    Good 24.64
    Total 81.64
    Feels Warm
    Excellent 30.88
    Very Good 28.92
    Good 25.98
    Total 85.78
    Does Not Feel Cold
    Excellent 54.37
    Very Good 29.61
    Good 10.19
    Total 94.53
  • [0061]
    As set forth in Table 3 above, 81.64% of the subjects registered a positive response that the product “warms on contact”, 85.78% subjects felt that the product “feels warm” while 94.53% subjects registered that the product “does not feel cold”.
  • EXAMPLE 4 Comparison Of Lubricity
  • [0062]
    Ahmad et al. in U.S. Pat. No. 6,139,848, which is hereby incorporated herein by reference, describe a method to test lubricity of various personal lubricants known to the trade. In the described test method, the lubricity of various marketed personal lubricants was determined over a period of 300 seconds (5 minutes). The lubricity data disclosed in this patent indicates that K-Y Liquid® lubricant had a higher lubricity and was longer lasting during the 300 seconds test period than the competitive products. The lubricity data set forth in U.S. Pat. No. 6,139,848 has a negative (−) sign during the “push” and positive (+) sign during the “pull” phase of the experiment. Compositions of this invention were tested using the lubricity test set foth in U.S. Pat. No. 6,129,848. However, the test duration was successfully extended to 16 minutes (960 seconds) and the data was treated to “curve-fit” to eliminate the negative (−) sign. The lubricity data for the composition 1 of this invention is compared with the data for K-Y Liquid® in FIG. 5. The data indicate that Composition 1 of this invention has a higher lubricity as compare to K-Y Liquid® and that Composition 1 maintains the high lubricity for an extended period of 16 minutes (960 minutes) and is therefore longer lasting.
  • EXAMPLES 5-9 Compositions of the Invention
  • [0063]
    The following compositions of this invention were made as follows: first, propylene glycol and glycerin were mixed. A preservative and the insulating agent were then added to the mixture in the same container. The mixture was then heated to from about 35° C. to about 45° C. to completely dissolve the preservative. The mixture was then cooled.
  • [0064]
    Composition 1:
    Propylene Glycol 50.00%
    Glycerin 45.00%
    Honey 5.00%
  • [0065]
    Composition 2:
    Propylene Glycol 50.00%
    Glycerin 20.00%
    Isopropyl Myristate 27.00%
    Polysorbate 60 3.00%
  • [0066]
    Composition 3:
    Propylene Glycol 95.00%
    Honey 5.00%
  • [0067]
    Composition 4:
    Propylene Glycol 50.00%
    Glycerin 20.00%
    Isopropyl Myristate 29.50%
    Klucel HF 0.50%
  • [0068]
    Composition 5:
    Propylene Glycol 99.50%
    Klucel HF 0.50%
  • [0069]
    Composition 6:
    Propylene Glycol 49.80%
    Glycerin 45.00%
    Honey 5.00%
    Preservative 0.20%
  • [0070]
    Composition 7:
    Miconazole Nitrate 2.00%
    Propylene Glycol 49.80%
    Glycerin 43.00%
    Honey 5.00%
    Preservative 0.20%
  • [0071]
    Composition 8:
    Fluconazole 2.00%
    Propylene Glycol 49.80%
    Glycerin 43.00%
    Honey 5.00%
    Preservative 0.20%
  • [0072]
    Composition 9:
    Metronidazole 3.00%
    Propylene Glycol 49.80%
    Glycerin 42.00%
    Honey 5.00%
    Preservative 0.20%
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4110426 *4 Mar 197629 Aug 1978Colgate-Palmolive CompanyMethod of treating skin and hair with a self-heated cosmetic
US4232003 *26 Nov 19754 Nov 1980Posthuma Albert ESynthetic physiological mucus
US4233876 *27 Jul 197818 Nov 1980Thomas LeahyMethod for preventing freeze-up of musical instrument valves and other movable elements
US4347237 *2 Mar 198131 Aug 1982Evenstad Kenneth LLower fatty acid glyceride high-HLB lubricating suppository and method for making and using the same
US4636520 *3 Jul 198513 Jan 1987Fujisawa Pharmaceutical Co., Ltd.Antifungal composition employing pyrrolnitrin in combination with an imidazole compound
US4720507 *5 Mar 198419 Jan 1988University Of Western OntarioBiological contraceptive and contraceptive technique for males
US4863725 *13 Sep 19845 Sep 1989Deckner George ENovel clear oil-free moisturizer composition
US4950475 *19 Jul 198821 Aug 1990Imaginative Research Associates, Inc.Novel film-forming gels with high concentrations of humectants and emollients
US4981686 *6 Sep 19881 Jan 1991Hardy Robert EPersonal lubricant
US5002938 *15 Mar 198926 Mar 1991Bristol-Myers Squibb CompanyAntifungal gel formulations
US5208031 *29 Jul 19914 May 1993Kelly Patrick DSexual lubricants containing zinc as an anti-viral agent
US5236609 *24 Jan 199117 Aug 1993Chas F Thackray LimitedSterilizable lubricant
US5270032 *6 Aug 199214 Dec 1993The Research Foundation Of State University Of New YorkComposition and method for the prevention and treatment of candidiasis
US5349149 *1 Apr 199220 Sep 1994Castrol Limited Burmah Castrol HouseDual-purpose fluid for cutting and electrical discharge machining
US5393528 *1 Jun 199328 Feb 1995Staab; Robert J.Dissolvable device for contraception or delivery of medication
US5512289 *8 Jun 199530 Apr 1996Johnson & Johnson Consumer Products, Inc.Spermicidal anti-viral lubricant composition and method of using same
US5513629 *20 Jan 19957 May 1996Dura Therm Inc.Microwavable heat releasing and absorbing composition and container
US5527534 *21 Oct 199318 Jun 1996Gynetech Laboratories, Ltd.Vaginal sponge delivery system
US5529782 *3 Nov 199425 Jun 1996Staab; RobertDissolvable device for contraception or delivery of medication
US5595980 *7 Apr 199521 Jan 1997Medical College Of Hampton RoadsContraceptive compositions
US5599551 *22 Dec 19944 Feb 1997Kelly; Patrick D.Genital lubricants containing zinc as an anti-viral agent
US5658583 *28 Jul 199519 Aug 1997Zhang; JieApparatus and methods for improved noninvasive dermal administration of pharmaceuticals
US5696164 *22 Dec 19949 Dec 1997Johnson & Johnson Consumer Products, Inc.Antifungal treatment of nails
US5709849 *3 Sep 199220 Jan 1998Shiseido Company LtdSuppressing stickiness to skin of cosmetic composition
US5840744 *15 Jul 199624 Nov 1998Minnesota Mining And Manufacturing Co.Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5885591 *29 May 199723 Mar 1999Johnson & Johnson Consumer Products, Inc.Personal lubricant compositions
US5895658 *17 Sep 199720 Apr 1999Fossel; Eric T.Topical delivery of L-arginine to cause tissue warming
US5902593 *1 Oct 199711 May 1999Kent; Frances B.Topically applied personal lubricant containing benzalkonium chloride as the active ingredient
US5976561 *16 Nov 19982 Nov 1999Kent; Frances B.Topically applied sensitizing gel and method of using the same
US5980875 *9 Apr 19979 Nov 1999Mousa; Mahmoud A.Honey preparations
US5980924 *19 Mar 19989 Nov 1999Kao CorporationSkin cleansing sheet
US6007846 *16 May 199728 Dec 1999Townley Jewelry, Inc.Scented body gel having particulate matter in the form of glitter with predetermined shapes
US6013270 *20 Apr 199811 Jan 2000The Procter & Gamble CompanySkin care kit
US6019782 *3 Dec 19971 Feb 2000The Procter & Gamble CompanyDisposable thermal body pad
US6060077 *4 Oct 19969 May 2000Laboratoire Innothera, Societe AnonymeUnit galenical formulation for local hormonotherapy of vaginal dryness
US6153208 *11 Sep 199828 Nov 2000The Procter & Gamble CompanyCleansing and conditioning article for skin or hair
US6171604 *7 Jul 19999 Jan 2001Mahmoud A. MousaHoney preparations
US6190680 *31 Mar 199920 Feb 2001The Nisshin Oil Mills, Ltd.Oily composition and process for producing the same
US6221814 *9 Apr 199924 Apr 2001Shin-Etsu Handotai Co., Ltd.Aqueous compositions, aqueous cutting fluid using the same, method for preparation thereof, and cutting method using the cutting fluid
US6303108 *15 Jun 199916 Oct 2001L'orealSolid warming pulverulent composition to be hydrated for caring for or cleaning the skin
US6328991 *30 Nov 199911 Dec 2001John MyhlingComposition and method for prevention of sexually transmitted diseases, including aids
US6338855 *22 Apr 199915 Jan 2002The Procter & Gamble CompanyCleansing articles for skin and/or hair which also deposit skin care actives
US6531171 *3 Jul 200111 Mar 2003Nutricia Usa, Inc.Food products containing betaine
US6641825 *30 Aug 20024 Nov 2003Henkel Kommanditgesellschaft Auf AktienSkin cleansing gel having a heating effect
US6664296 *21 Dec 199516 Dec 2003Laboratoire Innothera Societe AnonymeUnit galenical formulation for vaginal use as a local contraceptive and/or to combat sexually-transmitted diseases and/or HIV
US6706574 *17 May 200216 Mar 2004Raytheon CompanyField effect transistor and method for making the same
US6706674 *17 Jan 200116 Mar 2004The Andrew Jergens CompanyNonaqueous hair styling composition and method of use
US20020013304 *27 Jul 200131 Jan 2002Wilson Leland F.As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20020103414 *15 Nov 20011 Aug 2002Harrison Michael J.Condom with male genital desensitizer lubricant
US20030092754 *16 Jan 200215 May 2003Nishizumi NishimutaExternal preparation for skin diseases containing nitroimidazole
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US770942823 Feb 20054 May 2010Ansell Healthcare Products LlcThickened spreadable warming lubricant
US785141913 Apr 200614 Dec 2010Nawaz AhmadSubstantially anhydrous sprayable personal lubricant
US81931343 Mar 20105 Jun 2012Ansell Healthcare Products LlcThickened spreadable warming lubricant
US83039698 Apr 20106 Nov 2012Ansell Healthcare Products LlcSpreadable warming lubricant
US877020123 Oct 20088 Jul 2014Glycobiosciences Inc.Condom with multifunctional coating
US20060188528 *23 Feb 200524 Aug 2006Ansell Healthcare Products LlcSpreadable warming lubricant
US20060189493 *23 Feb 200524 Aug 2006Ansell Healthcare Products LlcThickened spreadable warming lubricant
US20070059250 *13 Apr 200615 Mar 2007Nawaz AhmadSprayable personal lubricant
US20070059266 *13 Apr 200615 Mar 2007Nawaz AhmadSprayable personal lubricant
US20090107513 *23 Oct 200830 Apr 2009Ansell Healthcare Products LlcCondom With Multifunctional Coating
US20100160457 *3 Mar 201024 Jun 2010Ansell Healthcare Products LlcThickened Spreadable Warming Lubricant
US20100186751 *8 Apr 201029 Jul 2010Ansell Healthcare Products LlcSpreadable Warming Lubricant
Classifications
U.S. Classification508/583, 514/967
International ClassificationA61P1/02, A61P15/18, A61P15/02, A61K45/00, A61P23/02, A61P15/00, A61P31/04, A61K31/429, A61K47/34, A61P15/16, A61P31/10, A61P31/12, A61K47/38, A61K31/496, A61K31/4174, A61K47/14, A61K47/10, A61K47/12, A61K9/00, A61K9/06, A61K47/46, A61K45/06, C10M105/14, A61K31/415
Cooperative ClassificationY10S514/967, Y10S424/14, Y10S514/944, A61K45/06, A61K9/0034, A61K9/06, A61K47/10, A61K47/14, A61K47/12, A61K47/46, A61K31/415, A61K47/38, A61K31/496, A61K31/4174
European ClassificationA61K31/415, A61K31/496, A61K9/06, A61K45/06, A61K31/4174, A61K9/00M8, A61K47/10, A61K47/12, A61K47/38